Assessment of Neuregulin4 function in patients with polycystic ovary syndrome disorder

Authors

  • Lara Balasim Al-Dahy
  • Yasir Khaleel Almusawi
  • Arwa Fadil Haqi Ballur

DOI:

https://doi.org/10.47750/pnr.2022.13.04.090

Keywords:

BMI, NRG4 and PCOS.

Abstract

Subject: Polycystic ovary syndrome (PCOS) is female disorder caused by cysts formation in ovarian that results disorder of hormones secretion and menstrual cycle. Neuregulin 4 (NRG4) is one of adipokines family members synthesis and release via adipose tissues, it acts as activator the epidermal growth factor receptor (EGFR).
Objective of the Study: Assessment role of NRG4 in PCOS patients.
Materials and Methods: Present study included 30 PCOS patients with 30 controls, the age individuals of tow group at study were 18 years and above of females. At this study measured serum NRG4 level by quantity method for all study individuals, the body mass index (BMI) also measured for all study individuals.
Results: Present study explain increase of NRG4 level in serum samples and BMI in PCOS patients group compared with control group.
Conclusion: Current study demonstrate role of NRG4 level that act as compensate mechanism in PCOS disorder.

Downloads

Published

2022-10-09

Issue

Section

Articles

How to Cite

Assessment of Neuregulin4 function in patients with polycystic ovary syndrome disorder. (2022). Journal of Pharmaceutical Negative Results, 13(4), 676-678. https://doi.org/10.47750/pnr.2022.13.04.090